NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

Partnership

Transforming Health & Care Systems (THCS)

Transforming Health & Care Systems (THCS)

Partnership website: https://www.thcspartnership.eu/

The partnership aims to contribute to the transition towards more sustainable, resilient, innovative and high-quality people-centred health and care systems. The partnership started its activities in January 2023. Flanders is actively involved.

The European Partnership 'Transforming Health & Care Systems' (THCS) pools a critical mass of European, national,  and regional and international scientific resources to address more efficiently  similar challenges faced by  health and care systems in Europe and beyond.

The partnership aims to create new knowledge and scientific evidence but also to co-design new solutions & support their transfer and scale-up across countries and regions.

The THCS consortium is mainly composed of a network of Ministries of Research & Innovation, Research & Innovation Funding Organisations and Ministries of Health or Regional Health & Care Authorities. It gathers partners from 64 organisations established in 23 EU Members States and associated countries.

Participation Flanders

Flanders is represented in the consortium by the Flanders Innovation & Entrepreneurship (VLAIO). Located in Flanders & interested to participate? Find out more on the dedicated VLAIO webpage.

Who can participate in Flanders? The target group is broad. All Flemish companies (both SMEs and large companies) that want to carry out a challenging and risky R&D project together with foreign companies, healthcare organizations and/or knowledge institutions can submit a project proposal.

Past call for proposals

The Partnership opened a first call for proposals with focus on 'healthcare of the future' beginning of 2023. The call is now closed and results are expected in Autumn 2023.

In february 2024, THCS launched its second Joint Transnational Call (JTC) for proposals aiming to support the implementation of innovative person-centred health and care models addressing prevention strategies, with the key help of existing IT and digital technologies and services.

You can register to the THCS newsletter here to be kept informed about future opportunities.

Key documents

Contact

Commission services: RTD-HS-PARTNERSHIP@ec.europa.eu

Partnership: info@thcspartnership.eu 

What are partnerships?

Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.

How to use partnerships?

  • orientation
    Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points.
  • networking
    Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents.
  • ecosystem analysis
    Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain.
  • steering the agenda
    Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.